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Catastrophe gradient drives anaphase B
I
t takes a polar catastrophe—oodles of them, actually—to 
get through anaphase, suggest Cheerambathur et al. on 
page 995. Their modeling reveals that concentrating 
  microtubule catastrophes near the spindle poles might drive 
the second half of anaphase.
Anaphase in ﬂ   y cells is a two-step process: ﬁ   rst the 
chromosomes migrate to the poles (anaphase A), then the 
spindle lengthens, pushing the DNA further apart (anaphase B). 
To understand the microtubule changes that lead to anaphase 
B, the authors combined modeling studies with in vivo obser-
vations of microtubule dynamics.
The experimental studies revealed that microtubule plus ends 
became concentrated in the central spindle at the onset of 
anaphase B. The changes were driven by cell cycle–regulated sig-
naling pathways, not by any intrinsic properties of microtubules.
Determining which spindle proteins are targeted by these 
pathways is tricky, however. Most candidates have a host of 
different mitotic functions, making speciﬁ  c effects difﬁ  cult to 
pick out. The group thus turned to computational modeling.
Only one of their envisioned scenarios accounted for both 
the plus-end redistribution and the rapid microtubule turnover 
dynamics in the spindle. In this model, microtubule plus ends 
near the poles were threefold more likely switch from growth to 
depolymerization—an event 
known as a catastrophe—than 
were plus ends at the midzone.
The authors imagine that 
losses at the poles concentrate 
plus ends in the midzone and 
thus make it more likely that a 
microtubule from one pole will 
capture a partner from the other 
pole. This bias should expand 
the microtubule overlap at the 
midzone, where the pushing 
forces that elongate the spindle 
are generated. The remaining 
short microtubules near the 
pole, meanwhile, probably 
keep hold of the chromosomes.
To test their model experi-
mentally, the group will have to 
screen for factors that affect this catastrophe gradient. It is not 
yet clear how the gradient is generated. Perhaps it reﬂ  ects a 
gradient of a depolymerase activity, such as kinesin-13, which 
is known to hover near the poles. 
Scarred by a death receptor
E
ven when it’s not killing, a death receptor still fi  nds ways to infl  ict damage. On page 1119, Sachs 
et al. show that a TNF receptor helps build scars that can get in the way of healing.
Tissue scars are formed from build-ups of extracellular matrix proteins. In particular, a blood-
clotting factor called fi  brin escapes from damaged vessels and is deposited as a temporary matrix in the 
tissue. The deposits can block nerve regeneration and cause lung and vascular diseases.
Fibrin’s degradation by plasmin allows healing to proceed more effi  ciently. Sachs and colleagues thus went 
looking for factors that either block or help this degradation. They had noticed that fi  brin deposits were often 
found in areas with high levels of the TNF receptor family member, p75NTR. Although usually associated with the 
nervous system, where it mainly activates apoptosis, p75NTR is also expressed in the liver and lung upon injury.
Mice lacking p75NTR now reveal that this death receptor prevents fi  brin degradation. The mutant mice had 
less fi  brin deposition upon nerve injury than did injured normal mice. Revved up plasmin activity accounted 
for the better degradation in the mutants. Plasmin can be turned on by two activators, tPA and uPA, but only 
tPA levels were higher in the mutants.
The gene for tPA is induced by cAMP signaling, which the 
authors found is dampened by p75NTR. They identifi  ed a binding 
site in the receptor for a specifi  c phosphodiesterase that targets 
cAMP degradation to the membrane. Although p75NTR also binds 
to neurotrophins, these extracellular ligands were not necessary 
for cAMP degradation. Receptor expression and recruitment of 
the phosphodiesterase seem to be enough.
tPA is the drug used immediately following strokes to prevent 
lasting brain damage. The drug Rolipram also reduces fi  brosis, via its 
broad-scale inhibition of phosphodiesterases. Both have unwanted 
side effects, however. A better, more specifi  c strategy to boost cAMP 
levels and fi  brinolysis might be to interfere with the interaction of 
p75NTR and its particular phosphodiesterase partner. 
Microtubule plus ends (green) 
become concentrated in 
the spindle midzone at 
anaphase B (bottom). 
The ﬁ  brin (red) that blocks nerve healing is degraded when p75NTR 
isn’t around (right) to dampen tPA levels.